AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
AMSTERDAM, The Netherlands, October 22 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announced today that its Chief Research Officer Laura van 't Veer has received a prestigious 2007 Breast Cancer Research Foundation Award from the Pink Ribbon Breast Cancer Research Foundation.
The Pink Ribbon 'Breast Cancer Research Foundation' granted in New York awards to 151 international breast cancer researchers with a total value of 32 M$.
Laura van 't Veer received one of the awards together with her colleagues Martine Piccart-Gebhardt, Fatima Cardoso and Beppe Viale for their work on the European 'MINDACT' trial in which specific predictive aspects of MammaPrint(R) breast cancer prognosis assay are further tested.
Since inception in 1993 by Evelyn Lauder, the Breast Cancer Research Foundation has been solely dedicated to providing critical funding for innovative clinical and genetic research at leading medical centers worldwide.
"Laura is deeply committed to convert discoveries made in the academic setting into clinically-relevant products for the benefit of cancer patients. She co-founded Agendia exactly for that purpose. Her meticulous work enabled Agendia to become the first company to obtain clearance from the US FDA for ...